MIPOGG Brazil 16 +17

The aim of the MIPOGG decision-support tool is to help healthcare professionals identify which of their patients with cancer have a higher likelihood of having an underlying cancer predisposition syndrome. This tool provides genetic referral guidelines for patients, aged 0-18 years, who are/have been diagnosed with cancer. The MIPOGG decision-support tool is not designed to replace a clinician’s judgment. A physician’s clinical judgment that a referral may or may not be appropriate should override the MIPOGG recommendations. The MIPOGG does not substitute the need for formal genetic counselling and assessment prior to genetic testing. This screening tool cannot reliably identify 100% of children with a cancer predisposition syndrome. It may suggest referrals for patients who are subsequently deemed not to have a cancer predisposition syndrome, or for patients in whom a cancer predisposition syndrome is not yet identified based on current knowledge. Alternatively, the MIPOGG may suggest that a referral is not needed. It is possible, in this scenario, that a patient may subsequently be diagnosed with a cancer predisposition syndrome with the advent of new research and knowledge, or with evolution in the patient’s clinical status. The MIPOGG recommendations are based on current scientific knowledge and will be updated at regular intervals, as relevant new scientific information becomes available. The date of the last update is published on the MIPOGG website and its associated application. The referenced articles are suggested readings, and do not constitute a complete list of all the relevant literature used to compile the guidelines. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means without the prior written permission of the copyright holder.